Skip to main content
Erschienen in: Current Cardiology Reports 8/2017

01.08.2017 | Valvular Heart Disease (T Kiefer, Section Editor)

Mitral Valve Disease: a Comprehensive Review

verfasst von: Serge C. Harb, Brian P. Griffin

Erschienen in: Current Cardiology Reports | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review aims to provide a comprehensive assessment of mitral valve disease, both mitral stenosis and mitral regurgitation, starting with an overview of the valve anatomy.

Recent Findings

The advent of three-dimensional imaging has allowed a better representation of the valve anatomy. Rheumatic disease is still the number one cause of mitral stenosis worldwide and percutaneous balloon mitral valvuloplasty remains the therapy of choice when indicated and in anatomically eligible patients. Mitral regurgitation (MR) is classified as primary (i.e., lesion in the mitral apparatus) or secondary (caused by left ventricular geometrical alterations). While surgery, preferably repair, is still the recommended therapy for severe primary MR, percutaneous approaches to repair and/or replace the mitral valve are being extensively investigated.

Summary

Mitral valve disease is common. A careful understanding of mitral valve anatomy and the disease processes that affect the valve are crucial for providing optimal patient care.
Literatur
1.
Zurück zum Zitat Van Mieghem NM, Piazza N, Anderson RH, Tzikas A, Nieman K, De Laat LE, et al. Anatomy of the mitral valvular complex and its implications for transcatheter interventions for mitral regurgitation. J Am Coll Cardiol. 2010;56(8):617–26. doi:10.1016/j.jacc.2010.04.030.CrossRefPubMed Van Mieghem NM, Piazza N, Anderson RH, Tzikas A, Nieman K, De Laat LE, et al. Anatomy of the mitral valvular complex and its implications for transcatheter interventions for mitral regurgitation. J Am Coll Cardiol. 2010;56(8):617–26. doi:10.​1016/​j.​jacc.​2010.​04.​030.CrossRefPubMed
2.
Zurück zum Zitat Perloff JK, Roberts WC. The mitral apparatus. Functional anatomy of mitral regurgitation. Circulation. 1972;46(2):227–39.CrossRefPubMed Perloff JK, Roberts WC. The mitral apparatus. Functional anatomy of mitral regurgitation. Circulation. 1972;46(2):227–39.CrossRefPubMed
3.
Zurück zum Zitat Anwar AM, Soliman OI, ten Cate FJ, Nemes A, McGhie JS, Krenning BJ, et al. True mitral annulus diameter is underestimated by two-dimensional echocardiography as evidenced by real-time three-dimensional echocardiography and magnetic resonance imaging. Int J Card Imaging. 2007;23(5):541–7. doi:10.1007/s10554-006-9181-9.CrossRef Anwar AM, Soliman OI, ten Cate FJ, Nemes A, McGhie JS, Krenning BJ, et al. True mitral annulus diameter is underestimated by two-dimensional echocardiography as evidenced by real-time three-dimensional echocardiography and magnetic resonance imaging. Int J Card Imaging. 2007;23(5):541–7. doi:10.​1007/​s10554-006-9181-9.CrossRef
8.
Zurück zum Zitat Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831–7. doi:10.1001/jama.290.21.2831.CrossRefPubMed Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831–7. doi:10.​1001/​jama.​290.​21.​2831.CrossRefPubMed
9.
Zurück zum Zitat Ruckman RN, Van Praagh R. Anatomic types of congenital mitral stenosis: report of 49 autopsy cases with consideration of diagnosis and surgical implications. Am J Cardiol. 1978;42(4):592–601.CrossRefPubMed Ruckman RN, Van Praagh R. Anatomic types of congenital mitral stenosis: report of 49 autopsy cases with consideration of diagnosis and surgical implications. Am J Cardiol. 1978;42(4):592–601.CrossRefPubMed
10.
Zurück zum Zitat Hugenholtz PG, Ryan TJ, Stein SW, Abelmann WH. The spectrum of pure mitral stenosis. Hemodynamic studies in relation to clinical disability. Am J Cardiol. 1962;10:773–84.CrossRefPubMed Hugenholtz PG, Ryan TJ, Stein SW, Abelmann WH. The spectrum of pure mitral stenosis. Hemodynamic studies in relation to clinical disability. Am J Cardiol. 1962;10:773–84.CrossRefPubMed
11.
Zurück zum Zitat Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr. 2009;22(1):1–23; quiz 101-2. doi:10.1016/j.echo.2008.11.029.CrossRefPubMed Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr. 2009;22(1):1–23; quiz 101-2. doi:10.​1016/​j.​echo.​2008.​11.​029.CrossRefPubMed
12.
Zurück zum Zitat •• Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(22):e57–185. doi:10.1016/j.Jacc.2014.02.536. This report constitues the AHA/ACC recommendations for the management of patients with valvular heart disease.CrossRefPubMed •• Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(22):e57–185. doi:10.​1016/​j.​Jacc.​2014.​02.​536. This report constitues the AHA/ACC recommendations for the management of patients with valvular heart disease.CrossRefPubMed
13.
Zurück zum Zitat •• Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. AHA/ACC focused update of the 2014 AHA/ACC guideline for the Management of Patients with Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017, 2017; doi:10.1016/j.Jacc.2017.03.011. This report is the recent (2017) AHA/ACC focused update of the valvular guidelines. •• Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. AHA/ACC focused update of the 2014 AHA/ACC guideline for the Management of Patients with Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017, 2017; doi:10.​1016/​j.​Jacc.​2017.​03.​011. This report is the recent (2017) AHA/ACC focused update of the valvular guidelines.
15.
Zurück zum Zitat Gorlin R, Gorlin SG. Hydraulic formula for calculation of the area of the stenotic mitral valve, other cardiac valves, and central circulatory shunts. I. Am Heart J. 1951;41(1):1–29.CrossRefPubMed Gorlin R, Gorlin SG. Hydraulic formula for calculation of the area of the stenotic mitral valve, other cardiac valves, and central circulatory shunts. I. Am Heart J. 1951;41(1):1–29.CrossRefPubMed
16.
Zurück zum Zitat Rodriguez L, Thomas JD, Monterroso V, Weyman AE, Harrigan P, Mueller LN, et al. Validation of the proximal flow convergence method. Calculation of orifice area in patients with mitral stenosis. Circulation. 1993;88(3):1157–65.CrossRefPubMed Rodriguez L, Thomas JD, Monterroso V, Weyman AE, Harrigan P, Mueller LN, et al. Validation of the proximal flow convergence method. Calculation of orifice area in patients with mitral stenosis. Circulation. 1993;88(3):1157–65.CrossRefPubMed
17.
Zurück zum Zitat Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J. 1988;60(4):299–308.CrossRefPubMedPubMedCentral Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J. 1988;60(4):299–308.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Luxereau P, Dorent R, De Gevigney G, Bruneval P, Chomette G, Delahaye G. Aetiology of surgically treated mitral regurgitation. Eur Heart J. 1991;12(Suppl B):2–4.CrossRefPubMed Luxereau P, Dorent R, De Gevigney G, Bruneval P, Chomette G, Delahaye G. Aetiology of surgically treated mitral regurgitation. Eur Heart J. 1991;12(Suppl B):2–4.CrossRefPubMed
20.
Zurück zum Zitat Carpentier A. Cardiac valve surgery—the “French correction”. J Thorac Cardiovasc Surg. 1983;86(3):323–37.PubMed Carpentier A. Cardiac valve surgery—the “French correction”. J Thorac Cardiovasc Surg. 1983;86(3):323–37.PubMed
21.
Zurück zum Zitat Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16(7):777–802. doi:10.1016/S0894-7317(03)00335-3.CrossRefPubMed Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16(7):777–802. doi:10.​1016/​S0894-7317(03)00335-3.CrossRefPubMed
22.
Zurück zum Zitat Chen CG, Thomas JD, Anconina J, Harrigan P, Mueller L, Picard MH, et al. Impact of impinging wall jet on color Doppler quantification of mitral regurgitation. Circulation. 1991;84(2):712–20.CrossRefPubMed Chen CG, Thomas JD, Anconina J, Harrigan P, Mueller L, Picard MH, et al. Impact of impinging wall jet on color Doppler quantification of mitral regurgitation. Circulation. 1991;84(2):712–20.CrossRefPubMed
23.
Zurück zum Zitat Marsan NA, Westenberg JJ, Ypenburg C, Delgado V, van Bommel RJ, Roes SD, et al. Quantification of functional mitral regurgitation by real-time 3D echocardiography: comparison with 3D velocity-encoded cardiac magnetic resonance. JACC Cardiovasc Imaging. 2009;2(11):1245–52. doi:10.1016/j.jcmg.2009.07.006.CrossRefPubMed Marsan NA, Westenberg JJ, Ypenburg C, Delgado V, van Bommel RJ, Roes SD, et al. Quantification of functional mitral regurgitation by real-time 3D echocardiography: comparison with 3D velocity-encoded cardiac magnetic resonance. JACC Cardiovasc Imaging. 2009;2(11):1245–52. doi:10.​1016/​j.​jcmg.​2009.​07.​006.CrossRefPubMed
24.
27.
Zurück zum Zitat • Smith PK, Puskas JD, Ascheim DD, Voisine P, Gelijns AC, Moskowitz AJ, et al. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med. 2014;371(23):2178–88. doi:10.1056/NEJMoa1410490. This study, along with the study referenced below, showed that surgical treatment of ischemic mitral regurgitation did not provide a clinically meanigful benefit.CrossRef • Smith PK, Puskas JD, Ascheim DD, Voisine P, Gelijns AC, Moskowitz AJ, et al. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med. 2014;371(23):2178–88. doi:10.​1056/​NEJMoa1410490. This study, along with the study referenced below, showed that surgical treatment of ischemic mitral regurgitation did not provide a clinically meanigful benefit.CrossRef
28.
Zurück zum Zitat • Michler RE, Smith PK, Parides MK, Ailawadi G, Thourani V, Moskowitz AJ, et al. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med. 2016;374(20):1932–41. doi:10.1056/NEJMoa1602003. This study reports the 2-year outcomes of the surgical treatment of ischemic mitral regurgitation, similarly showing the lack of benefit.CrossRef • Michler RE, Smith PK, Parides MK, Ailawadi G, Thourani V, Moskowitz AJ, et al. Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med. 2016;374(20):1932–41. doi:10.​1056/​NEJMoa1602003. This study reports the 2-year outcomes of the surgical treatment of ischemic mitral regurgitation, similarly showing the lack of benefit.CrossRef
29.
Zurück zum Zitat • Acker MA, Parides MK, Perrault LP, Moskowitz AJ, Gelijns AC, Voisine P, et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med. 2014;370(1):23–32. doi:10.1056/NEJMoa1312808. This study shows no significant difference between patients who underwent mitral-valve repair and those who underwent mitral-valve replacement.CrossRef • Acker MA, Parides MK, Perrault LP, Moskowitz AJ, Gelijns AC, Voisine P, et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med. 2014;370(1):23–32. doi:10.​1056/​NEJMoa1312808. This study shows no significant difference between patients who underwent mitral-valve repair and those who underwent mitral-valve replacement.CrossRef
30.
Zurück zum Zitat Goldstein D, Moskowitz AJ, Gelijns AC, Ailawadi G, Parides MK, Perrault LP, et al. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N Engl J Med. 2016;374(4):344–53. doi:10.1056/NEJMoa1512913.CrossRefPubMed Goldstein D, Moskowitz AJ, Gelijns AC, Ailawadi G, Parides MK, Perrault LP, et al. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N Engl J Med. 2016;374(4):344–53. doi:10.​1056/​NEJMoa1512913.CrossRefPubMed
31.
Zurück zum Zitat Alashi A, Mentias A, Patel K, Gillinov AM, Sabik JF, Popovic ZB, et al. Synergistic utility of brain natriuretic peptide and left ventricular global longitudinal strain in asymptomatic patients with significant primary mitral regurgitation and preserved systolic function undergoing mitral valve surgery. Circ Cardiovasc Imaging. 2016;9(7) doi:10.1161/CIRCIMAGING.115.004451. Alashi A, Mentias A, Patel K, Gillinov AM, Sabik JF, Popovic ZB, et al. Synergistic utility of brain natriuretic peptide and left ventricular global longitudinal strain in asymptomatic patients with significant primary mitral regurgitation and preserved systolic function undergoing mitral valve surgery. Circ Cardiovasc Imaging. 2016;9(7) doi:10.​1161/​CIRCIMAGING.​115.​004451.
32.
Zurück zum Zitat Mentias A, Naji P, Gillinov AM, Rodriguez LL, Reed G, Mihaljevic T, et al. Strain echocardiography and functional capacity in asymptomatic primary mitral regurgitation with preserved ejection fraction. J Am Coll Cardiol. 2016;68(18):1974–86. doi:10.1016/j.jacc.2016.08.030.CrossRefPubMed Mentias A, Naji P, Gillinov AM, Rodriguez LL, Reed G, Mihaljevic T, et al. Strain echocardiography and functional capacity in asymptomatic primary mitral regurgitation with preserved ejection fraction. J Am Coll Cardiol. 2016;68(18):1974–86. doi:10.​1016/​j.​jacc.​2016.​08.​030.CrossRefPubMed
33.
Zurück zum Zitat Mentias A, Naji P, Barr T, Gillinov AM, Rodriguez LL, Mihaljevic T, et al. Incremental prognostic utility of LV global longitudinal strain and functional capacity in asymptomatic patients with significant primary mitral regurgitation and preserved left ventricular ejection fraction undergoing rest-stress echocardiography. Circulation. 2015;132 Mentias A, Naji P, Barr T, Gillinov AM, Rodriguez LL, Mihaljevic T, et al. Incremental prognostic utility of LV global longitudinal strain and functional capacity in asymptomatic patients with significant primary mitral regurgitation and preserved left ventricular ejection fraction undergoing rest-stress echocardiography. Circulation. 2015;132
34.
Metadaten
Titel
Mitral Valve Disease: a Comprehensive Review
verfasst von
Serge C. Harb
Brian P. Griffin
Publikationsdatum
01.08.2017
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 8/2017
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-017-0883-5

Weitere Artikel der Ausgabe 8/2017

Current Cardiology Reports 8/2017 Zur Ausgabe

Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

PCSK9 Inhibitors: Treating the Right Patients in Daily Practice

Management of Acute Coronary Syndromes (AS Jaffe, Section Editor)

Novel Risk Stratification Assays for Acute Coronary Syndrome

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.